Intrinsiqq
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc.

FENC

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$385M
EPS$0.02
P/E566.74
P/FCF122.21
EV/EBITDA90.38
FCF Yield0.8%
Div. Yield–
Net Debt/FCF-15.5x
Fennec Pharmaceuticals Inc. intrinsic value
52-Week Range
$5.77$12.78

Profitability & Returns

Revenue (TTM)

$66M

▼ -6.1% YoY

Net Income (TTM)

$2M

▼ -2134.2% YoY

Op. Margin

5.60%

▼ -19.5pp YoY

ROIC

7.13%

▼ -26.9pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

$3M

▼ -146.2% YoY

Op. Cash Flow (TTM)

$3M

▼ -146.2% YoY

Net Debt

-$49M

Net Cash Position

Cash & Equiv.

$49M

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with FENC

CompareIntrinsic value
RXRXRecursion Pharmaceuticals, Inc.
$3.33-7.24%25
GLUEMonte Rosa Therapeutics, Inc.
$9.53-7.57%10
CSBRChampions Oncology, Inc.
$4.65-2.72%26
CGENCompugen Ltd.
$2.12+1.44%75
IVVDInvivyd Inc.
$0.57-5.29%10
CHRSCoherus Biosciences Inc.
$0.55-5.18%10
PTHSPelthos Therapeutics Inc.
$8.03-14.48%0
EDITEditas Medicine Inc.
$2.14-10.08%40

Held by ETFs

FENC is in 5 US ETFs. The largest of them, with FENC's weight in each:

Fennec Pharmaceuticals (FENC) in four numbers

Fair value (earnings)
$0.55
Price $10.90 is 1879% above it.
Intrinsic Value
Quality score
50/100
Best check: revenue growth, 156.4%. Weakest: return on capital, 7.1%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
566.74
Price to free cash flow 122.21.
Financials

Questions about Fennec Pharmaceuticals

Is Fennec Pharmaceuticals (FENC) overvalued?

At $10.90, Fennec Pharmaceuticals' price is 1879% above the $0.55 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 566.74 times earnings and 122.21 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Fennec Pharmaceuticals' fair value?

Intrinsiqq's calculator puts Fennec Pharmaceuticals' fair value at $0.55 a share. It grows earnings per share 5% a year for 5 years, applies an exit P/E of 12.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.41. Every input can be changed on the Intrinsic Value tab.

Is Fennec Pharmaceuticals a high-quality business?

Fennec Pharmaceuticals scores 50 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 8 checks computed from SEC filings. Its best check is revenue growth at 156.4%, and its weakest is return on capital at 7.1%. The Quality tab shows every check against its target.

Does Fennec Pharmaceuticals (FENC) pay a dividend?

No. Fennec Pharmaceuticals (FENC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 10 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 12 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in FENC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing FENC

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.